Clinical Trial

A Phase 2b, Randomized, Double-blind Study of Redasemtide (S-005151) in Adult Participants With Acute Ischemic Stroke

Study acronym: Revive
Completed Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the efficacy and safety of redasemtide in adult participants with acute ischemic stroke (AIS). This study consists of 2 cohorts, Cohort A and Cohort B. Cohort A (redasemtide or placebo) will enroll participants who are ineligible for systemic thrombolysis and/or mechanical recanalization therapy. Cohort B (redasemtide or placebo) will enroll participants who are eligible to receive or who have received systemic thrombolysis and/or mechanical recanalization therapy as standard of care.
Protocol Amendment History 3 changes
critical Trial completed 2026-07-31
notable Primary completion pushed: 2026-03-31 -> 2026-06-30 2026-05-07
minor Completion pushed: 2026-03-31 -> 2026-06-30 2026-05-07
Trial Details
NCT Number NCT05953480
Lead Sponsor Shionogi
Conditions Acute Ischemic Stroke
Enrollment 680 participants
Start Date 2023-07-14
Primary Completion 2026-06-15 (estimated)
Study Completion 2026-06-15 (estimated)
Updated on ClinicalTrials.gov 2026-07-30